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The kinase receptor encoded by the Met oncogene is a sensible target for cancer therapy.
The chimeric monovalent Fab fragment of the DN30 monoclonal antibody (MvDN30) has
an odd mechanism of action, based on cell surface removal of Met via activation of specific
plasma membrane proteases. However, the short half-life of the Fab, due to its low molec-
ular weight, is a severe limitation for the deployment in therapy. This issue was addressed
by increasing the Fab molecular weight above the glomerular filtration threshold through
the duplication of the constant domains, in tandem (DCD-1) or reciprocally swapped (DCD-
2). The two newly engineered molecules showed biochemical properties comparable to the
original MvDN30 in vitro, acting as full Met antagonists, impairing Met phosphorylation and
activation of downstream signaling pathways. As a consequence, Met-mediated biological
responses were inhibited, including anchorage-dependent and -independent cell growth.
In vivo DCD-1 and DCD-2 showed a pharmacokinetic profile significantly improved over
the original MvDN30, doubling the circulating half-life and reducing the clearance. In
pre-clinical models of cancer, generated by injection of tumor cells or implant of patient-
derived samples, systemic administration of the engineered molecules inhibited the
growth of Met-addicted tumors.
ª 2016 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
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2010; Skead and Govender, 2015). Inmost instances, Met acti-
vation, by overexpression and/or ligand activation, contrib-
utes to tumor progression, fostering an adaptive response
to unfavorable micro environmental conditions (oncogene
‘expedience’) (Comoglio et al., 2008). In a limited number of
cases (2e3%), a Met genetic lesion (mutation or amplification)
directly drives transformation and the cancer cell relies on
the oncogene for the long term maintenance of the malig-
nant phenotype (oncogenic addiction) (Smolen et al., 2006;
Lutterbach et al., 2007). Met oncogene overexpression is
observed in many types of carcinomas and is strongly asso-
ciated with poor prognosis (Blumenschein et al., 2012; Gao
et al., 2015). An autocrine loop is more typical of non-
epithelial tumors such as osteosarcomas (Ferracini et al.,
1995), rhabdomyosarcomas (Ferracini et al., 1996), glioblas-
tomas (Moriyama et al., 1999), multiple myelomas (B€orset
et al., 1996), acute myeloid leukemias (Kentsis et al., 2012)
and mesotheliomas (Mukohara et al., 2005). Point mutations
were observed initially in sporadic and hereditary papillary
renal carcinomas (Schmidt et al., 1997). High frequency of
Met mutations has been scored in metastatic diseases
(Lorenzato et al., 2002; Stella et al., 2011). Met gene amplifica-
tion has been observed in cases of primary glioblastoma (Chi
et al., 2012), gastric-esophageal (Catenacci et al., 2011;
Lennerz et al., 2011) and lung carcinomas (Ou et al., 2011).
Moreover, Met amplification represents a mechanism
responsible for resistance to Epithelial Growth Factor Recep-
tor (EGFR) targeted therapies in Non-Small Cell Lung Cancer
(NSCLC) (Bean et al., 2007; Engelman et al., 2007) and Colo-
Rectal Cancer (CRC) patients (Bardelli et al., 2013).
A number of inhibitors blocking the HGF-Met axis through a
variety of mechanisms - small molecule Met kinase inhibitors,
monoclonal antibodies against HGF orMet, ligand competitors,
receptor decoys and anticalinse are currently available (Skead
and Govender, 2015). Among them, the monoclonal antibody
DN30 displays an odd mechanism of action, enhancing the
physiological rate of Met shedding (Petrelli et al., 2006). This
leads concomitantly to reduction of theMetmolecules exposed
at the cell surface and to release, in the extracellular environ-
ment, of the entire N-terminal Met domain (Lefebvre et al.,
2012), which competes with the full size receptor dimerization
(Michieli et al., 2004). As a consequence, Met-mediated biolog-
ical responses are strongly impaired. In its native bivalent
form, theDN30 antibody displays a paradoxicalMet agonist ac-
tivity, resulting in a week activation of the invasive growth
phenotype (Prat et al., 1998). Conversion to a monovalent
form (Fab fragment e MvDN30) translates the antibody into a
full antagonist, with potent inhibitory features, counteracting
both the HGF-dependent and -independent Met activation
(Pacchiana et al., 2010; Vigna et al., 2015).
MvDN30-Fab is thus an attractive drug for clinical applica-
tions, but the short plasma half-life e typical of Fab fragments
andmostly due to renal clearance e severely limits the clinical
application. A rational approach to address this issue is to in-
crease the molecular weight of the therapeutic protein above
the threshold of the glomerular filtration. To this endwe dupli-
cated the constant domainsof light andheavy chains. Thisnew
class of engineered proteins, named Dual Constant Domain-
Fab (DCD), was challenged against Met-addicted cancer cells.2. Material and methods
2.1. Construction, expression and purification of DCD
molecules
Molecules have been designed by duplication of the human
constant regions on the cDNA sequence of the MvDN30.
cDNA synthesis, protein expression in mammalian HEK293E
cells and subsequent Strep-Tactin purification of MvDN30,
DCD-1, DCD-2 and chimeric DN30 mAb were performed by
U-Protein Express BV (Utrecht, The Netherlands). Analysis of
the purified molecules was performed by SDS-PAGE of
200 ng of DCD-1, DCD-2 and MvDN30 as control under
reducing and non-reducing conditions, followed by GelCode
Blue Stain reagent (Pierce, Waltham, MA).
2.2. ELISA assays
For affinity determinations, pure recombinant human Met-Fc
chimera (R&D Systems, Minneapolis, MN) (100 ng/well) was in
solid phase and pure MvDN30, DCD-1 or DCD-2 (range of dilu-
tions: 0e36 nM) were in liquid phase; for quantification of the
molecules in themice serum, collected samples (range of dilu-
tions: 0e160000) were in liquid phase. Revealing was done
with HRP-conjugated anti-strepTAG II antibody (IBA, Goettin-
gen, Germany). Colorimetric assay was quantified by the
multi-label reader VICTOR X4 (Perkin Elmer Instrument INC.,
Whaltman, MA).
2.3. Cell culture
A549 human lung carcinoma cells, SNU-5 human gastric car-
cinoma cells and HPAF-II human pancreatic adenocarcinoma
cells were obtained fromATCC/LGC Standards S.r.l. (Sesto San
Giovanni, Italy). MKN-45 human gastric carcinoma cells were
obtained from the Japanese Collection of Research Bio-
resources (Osaka, Japan). GTL-16 were derived from MKN-
45 cells (Giordano et al., 1988). Cells were maintained in
RPMI medium (Sigma Life Science, St Louis, MO) as described
(Pacchiana et al., 2010).
M162 colon cancer cells were derived from tumor material
of a patient resistant to EGFR targeted therapy (Bardelli et al.,
2013) propagated (one step) inmice. Tumor extracted from the
animal was chopped, washed by PBS and centrifuged. Pellet
was re-suspended in Leibovitz’s L-15 medium (Gibco Life
technologies Italia, Monza, Italy) plus 2 mg/ml Collagenase I
(Sigma Life Sciences) incubated for 1 h at 37 C on shake. After
a passage on 70 micron filter, tumor cells were subjected to
Histopaque (Sigma Life Science) and collected from themono-
nucleated fraction. The obtained cells were seeded and
cultured as monolayer in DMEM-F12 medium with 20% FBS
added of 1%N-2 supplement (Thermo Fisher Scientific,Whalt-
man, MA) and 10 mM ROCK1 inhibitor Y-27632-2HCl (Selleck-
chem.com, Munich, Germany).
2.4. Met shedding analysis
Sub-confluent A549 andGTL-16monolayerswere incubated in
serum-free medium with increasing concentrations of
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(A549) or 18 h (GTL-16), conditioned medium was collected
and cells were lysed with Laemmli Buffer. Cell extracts and
cell culture supernatants were resolved by SDS-PAGE and
analyzed by Western blotting.
2.5. Met activation analysis
For the analysis of the agonistic activity, sub-confluent A549
monolayers were serum starved for 48 h. Then cells were
stimulated for 15 min at 37 C in serum-free medium with
two different concentrations of MvDN30, DCD-1 and DCD-2
(500 and 1000 nM). As positive control cells were also stimu-
lated with 500 nM of DN30 mAb or 100 ng/ml (1.1 nM) of re-
combinant HGF (R&D Systems). Cells were lysed as described
(Vigna et al., 2015). Total cell lysates were analyzed by West-
ern blot.
For theanalysisof the inhibitoryactivity, sub-confluentA549
monolayerswere incubated in serum-freemediumwith a fixed
concentration (1000nM) ofMvDN30,DCD-1 orDCD-2.After 24h
cells were stimulated with 100 ng/ml of HGF for 10min at 37 C
andsubsequently lysedandanalyzedasabove. ForGTL-16, sub-
confluentmonolayers were incubatedwith the different tested
molecules (500 nM) for 30 h, then lysed and analyzed as above.
2.6. Western blot analysis
Primary antibodies for Western blot detection were: anti-
human Met 3D4 mAb recognizing Met b chain intracellular
domain (Invitrogen Corporation, Camarillo, CA), anti-human
Met DL21 mAb recognizing Met b chain extracellular domain
(Vigna et al., 2008), anti-pMet Tyr1234/1235 (D26), anti-pAKT
Ser473, anti-AKT, anti-pERK1/2 Thr202/Tyr204, anti-ERK1/2
polyclonal Abs (all from Cell Signaling Technology, Beverly,
MA); anti-actin (I-19) (Santa Cruz Biotechnology Inc., Heidel-
berg, Germany); anti-Vinculin clone hVIN-1 (Sigma Life Sci-
ences). Secondary anti-mouse IgG, anti-rabbit IgG and anti-
goat IgG were from GE Healthcare (Freiburg, Germany).
2.7. In vitro biological assays
For scatter assay, HPAF-II cells were seeded in a 96 well plate
(8000 cells/well). After 24 h cells were stimulated with HGF
(5 ng/ml) or treated with MvDN30, DCD-1, DCD-2, chimeric
DN30 mAb (all molecules 200 nM) and stained with crystal vi-
olet (SigmaeAldrich, St Louis, MO) 20 h later. Cell scattering
was determined by microscopy.
For anchorage-dependent cell growth, cells were seeded as
described (Pacchiana et al., 2010). After 24 h, medium was
replaced with a fresh one with 5% FBS plus the molecules to
be tested (increasing concentrations e from 0.0032 to 10 mM
e for Met-addicted cell line analysis or a fixed dose 2 mM-
for theM162 cells). Cell viability was evaluated after 72 h using
the CellTiter-Glo luminescent cell viability assay (Promega
Corp., Madison, WI), according to the manufacturer’s instruc-
tions. Chemiluminescence was detected with VICTOR X4.
For anchorage-independent cell growth, cells (500 cells/
well) were seeded in a 48 well plate in semisolid medium as
described (Pacchiana et al., 2010). GTL-16 were treated with
two different concentrations of the tested molecules (1.5 and0.75 mM), while A549 were treated with a single concentration
of the testedmolecules (1.5 mM), in absence or presence of HGF
(50 ng/ml). Fresh medium was replaced every 3 days. Grown
colonieswere stained by tetrazolium salts (SigmaeAldrich) af-
ter 11 days (GTL-16) or 21 days (A549) of culture. Growth was
evaluated analyzing the images from each sample with Meta-
morph software (Molecular Devices, Sunnyvale, CA).
2.8. Pharmacokinetic analysis
All animal procedures were performed according to protocols
approved by Ethical Committee for animal experimentation
of Fondazione Piemontese per la Ricerca sul Cancroandby Ital-
ianMinistry ofHealth.Adult immunodeficientNOD-SCIDmice
(body weight between 18 and 22 gr, on average 20 gr) were
injected intraperitoneally or intravenously (via tail vein) with
100 mg (5 mg/kg) of DCD-1, DCD-2, MvDN30 or chimeric DN30
mAb (the latter only via tail vein). Peripheral blood was
collected at different time points. The amounts of the different
molecules in the serum were evaluated by ELISA as described
above. Concentrations of DN30-derived molecules were ob-
tained interpolating the absorbance values of the samples on
the linear part of a standard curve obtained by serial dilutions
of the different purified molecules. Each time point was the
average value of at least 3 mice. Pharmacokinetic parameters
were calculated analyzing the concentration values with the
software Kinetica 4.1.1 (InnaPhase Corp, Philadelphia, PA).
2.9. Tumorigenesis assays
6 week-old female NOD/SCID mice were intraperitoneally
injected with luciferase-expressing GTL-16 cells
(2  106 cells/mouse). Expression of the luciferase gene has
been obtained by transduction with 100 ng/ml p24 of lentiviral
vectors carrying the luciferase gene under the control of the
CMV promoter as described (Amendola et al., 2005; Vigna
et al., 2008). Mice were immediately randomized in four
groups (n ¼ 6) and treated twice a week from day 0 to the
end of the experiment (day 24) with intravenous administra-
tions of MvDN30, DCD-1, DCD-2 (8 nmol/mouse) or PBS
(vehicle). At the end of the experiment, mice received Xeno-
Light D-Luciferin (PerkinElmer) (3 mg/mouse) by intraperito-
neal injection. The luminescent signal was revealed and
quantified in each single animal and in the omentum
collected upon sacrifice.
M162 ‘xenopatient’ tumor samples were implanted in the
right flank of 6 week-old female NOD/SCID mice. Mice were
immediately randomized in 3 groups (n ¼ 7 Control and DCD-
2; n ¼ 5 DCD-1) and treated twice a week from day 0 to the end
of the experiment (day 39) with intraperitoneal injections of
DCD-1 and DCD-2 (7 nmol/mouse) or PBS (vehicle). Tumor size
wasevaluatedperiodicallywithacaliper;micewereconsidered
tumor positive whenmasses reached a volume of 20 mm3.
2.10. Statistical analysis
To calculate Kd and Bmax, data from ELISA assays were
analyzed and fitted according to nonlinear regression, one
site binding (hyperbola) curve, using GraphPad Prism software
(San Diego, CA). Data from growth assays were analyzed and
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response curve, using GraphPad Prism software. Averages,
standard errors of the mean (SEM) and p values obtained by
Student’s t Test and by two-way ANOVAwere calculated using
GraphPad Prism software.3. Results
3.1. Design, synthesis and purification of the Dual
Constant Domain Fab
To generate engineered molecules derived from the chimeric
MvDN30, the constant domains in the light and heavy chains
were duplicated (Dual Constant Domain-MvDN30, DCD). The
predicted molecular weight is 75 kDa, which is above the
threshold of glomerular filtration. Two different molecules
were engineered: (i) DCD-1, built by duplication in tandem of
the human constant domains, generating a VH-CH1-CH1
heavy chain and a VL-CL-CL light chain; (ii) DCD-2, engineered
by reciprocal swap of the terminal domains, generating a VH-
CH1-CL heavy chain and a VL-CL-CH1 light chain (Figure 1A).
The purified recombinant proteins, analyzed under reducing
conditions, showed the expected molecular weight (i.e. two
bands corresponding to the Fab light and heavy chains with
the added sequences), while under non-reducing conditions,
DCD-1 formed dimers and oligomers and DCD-2 preferentially
generated oligomers, as probably the swap between the termi-
nal constant domains forced the joint between multiple
chains (Figure 1B and C). Oligomerization results from inter-
molecule disulfide bonds between the cysteine residues of
the heavy and light constant domains (data not shown).3.2. DCD-1 and DCD-2 bind Met with high affinity,
inducing Met shedding
Purified DCD-1, DCD-2 and MvDN30 as a control, analyzed by
ELISA, bound Met with similar high affinity (Figure 2A). The
maximal saturation values were higher for both DCDs versusFigure 1 e DCDs appear associated by disulfide bonds in dimers and oligomers
Domain molecules (DCD-1 and DCD-2). VH: variable domain derived from
IgG1 heavy chain. Strep His TAGs: sequences included for detection and
light chain. CL: constant domain derived from human Igk light chain. B.
conditions, followed by staining with GelCode Blue Stain reagent. C. Schthe MvDN30, as expected by the conformation of the former,
including more than one Strep-TAG epitope per molecule
(cfr Figure 1C). Upon binding to Met, both DCDs efficiently
induced Met shedding in human cancer cells of different
origin (A549 lung and GTL-16 gastric carcinoma cells). As for
the parental MvDN30, DCD binding to the surface resulted in
decrease of Met levels in the cell and in release of soluble
Met ectodomain in the extracellular space, accordingly to
the antibody-derivative given dose (Figure 2B).
3.3. DCD-1 and DCD-2 act as pure Met antagonists
To assess if DCDs are endowed with residual agonist prop-
erties towards Met, A549 carcinoma cells, expressing Met
receptors prone to activation by HGF or ligand-mimetic
molecules, were stimulated by increasing amounts of
DCD-1 or DCD-2. HGF, DN30 bivalent mAb or monovalent
MvDN30 were included as positive or negative controls.
DCD-1 and DCD-2 retained a minimal residual agonist ac-
tivity on Met phosphorylation, negligible compared to HGF
or DN30 mAb. Activation of downstream signal transducers
did not occur (Figure 3A). Accordingly, both molecules did
not evoke biological responses, as assessed by analysis of
the highly sensitive scatter assay (Figure 3B). On the other
hand, a strong DCD inhibitory activity was measured in
A549 stimulated with HGF and in GTL-16 cells, featuring
constitutively active Met. In both systems, DCD-1 and
DCD-2 efficiently impaired the level of Met phosphoryla-
tion, resulting in inhibition of downstream activation of
AKT and ERK (Figure 4A, B).
3.4. DCD-1 and DCD-2 inhibit Met-mediated biological
responses in vitro
Cell growth impairment was evaluated in a panel of Met-
addicted carcinoma cell lines featuring Met amplification
(GTL-16, MKN-45, SNU-5). DCD-1 and DCD-2 inhibited cell
growth in a dose-dependent manner, in most cases with
a potency similar to MvDN30 (Figure 5A and
Supplementary Figure 1A, B). As expected, cells that are. A. Schematic representation of MvDN30 and of the Dual Constant
DN30 heavy chain. CH1: first constant domain derived from human
purification of the proteins. VL: variable domain derived from DN30
SDS-PAGE in polyacrylamide gel under reducing and non-reducing
















Figure 2 e DCDs maintain high binding affinity to Met and efficient induction of receptor shedding. A. ELISA binding analysis of Met-Fc chimera
(solid phase) to the different DN30-derived molecules (liquid phase). O.D.: Optical Density at 450 nm; A.U.: Arbitrary Unit. Each point is the
mean of triplicate values. Bars represent SEM. Values of Affinity (Kd) and Maximal Binding (Bmax) are reported in the table. B. A549 (left panels)
or GTL-16 (right panels) cells were incubated with increasing concentrations of the indicated molecules for 48 h (A549) or 18 h (GTL-16). Total
Met levels in the cell lysates (upper panels) and in the cell culture supernatants (lower panels) were determined by Western blot using anti-Met
antibodies directed against epitopes located respectively at the c-terminal tail or within the extracellular domain of the b chain. To normalize
protein loading, the same filter was re-probed with anti-actin antibodies. p190 Met: unprocessed Met receptor; p145 Met: Met receptor b chain;
p80 Met: Met extracellular domain. p47 actin: actin. Data reported in the figure are representative of at least three experiments done.
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DCD-2 inhibition (Supplementary Figure 2A). Inhibition of
anchorage-independent cell growth was tested in
A549 cells stimulated or not with HGF and in GTL-16 cells
carrying a constitutively phosphorylated Met. Against
A549, DCD-2 strongly reduced HGF-induced colony forma-
tion in semisolid medium while DCD-1 was less effective
(Figure 5B). If HGF was not added, all the molecules did
not display any inhibitor activity (Supplementary
Figure 2B). Against GTL-16, DCD-1 and DCD-2 were simi-
larly potent, with a reduced performance compared to
MvDN30 (Figure 5C).3.5. DCD-1 and DCD-2 show improved
pharmacokinetics
To evaluate the pharmacokinetics of the two new molecules,
a single dose of DCD-1, DCD-2 or MvDN30 e as control e was
delivered, either intraperitoneally or intravenously, toimmunocompromised mice and the serum concentrations
were determined by ELISA assay. The kinetics of the anti-
Met molecules administered by intraperitoneal injection
are reported in Figure 6A, as well as the corresponding phar-
macokinetic parameters. Compared to MvDN30, the newly
engineered molecules showed: (i) more than three folds
higher maximal circulating concentration (Cmax); (ii) around
two folds longer circulating half-life (t1/2 elim); (iii) clear-
ance and blood systemic exposure (tot AUC) ten or thirteen
folds improved (DCD-1 and DCD-2 respectively) versus con-
trol. Intravenous administration confirmed a clear improve-
ment of DCD-1 and DCD-2 pharmacokinetic profiles versus
MvDN30. In the direct comparison with the chimeric DN30
full size antibody, included in the analysis as positive
control, the new molecules showed a limited loss in distri-
bution half-life, clearance and blood systemic exposure,
while elimination half-life and terminal elimination rate (k
elim) reached values similar to the full size antibody
(Figure 6B).
Figure 3 e DCDs do not show Met agonistic properties A. A549 cells stimulated with increasing concentrations of MvDN30, DCD-1 or DCD-2 and
analyzed by Western blot for Met, AKT and ERK activation. As positive control, cells were also stimulated with the indicated concentrations of
pure HGF or chimeric DN30 mAb. To normalize protein loading, the same filter was re-probed with anti-vinculin antibodies. Data reported in the
figure are representative of at least three experiments done. B. HPAF-II cells treated with MvDN30, DCD-1, DCD-2 (200 nM), HGF (5 ng/ml)
or chimeric DN30 mAb (200 nM) for 18 h. Pictures are representative of the cell phenotype: control cells grew in compact islands, while HGF-
treated cells appeared as single cells separated from each other (scattered). Some scattered islands were found in the chimeric DN30 mAb treated
cells. Stimulation with MvDN30, DCD-1 or DCD-2 did not induce cell motility, appearing indistinguishable from controls. Pictures are
representative of two experiments done.
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growth in vivo
Met-addicted GTL-16 cells, expressing luciferase by lentiviral
vector transduction, were intraperitoneally injected in immu-
nodeficient mice. The animals were randomized and treated
by intravenous injection with MvDN30, DCD-1, DCD-2 or
vehicle. The number and the volume of the tumor foci were
evaluated by measuring the total luminescence with the IVIS
imaging system. Treatments with the newly engineeredFigure 4 e DCDs inhibit Met activation. A. A549 cells treated for 24 h wit
stimulated with HGF (100 ng/ml) for 15 min. B. GTL-16 cells treated for 30
of Met, AKT and ERK activation was analyzed for both cell lines. To norm
antibodies. Data reported in the figure are representative of at least three emolecules were effective: a significant reduction in number
and size of tumor foci was scored, compared to both vehicle
and MvDN30 administrations (Figure 7A, B).
3.7. DCD-1 and DCD-2 inhibit the growth of a Met-
amplified patient-derived colon carcinoma in vivo
Taking advantage of the ‘xenopatients’ platform available in
our institute (Bertotti et al., 2011), the engineered inhibitors
were tested against M162, a patient-derived colorectalh the indicated amount of MvDN30, DCD-1 or DCD-2 and then
h with the indicated amount of the same above molecules. Activation
alize protein loading, the same filter was re-probed with anti-vinculin
xperiments done.
Figure 5 e DCDs inhibit Met-mediated anchorage-dependent and -independent tumor cell growth in vitro. A. Growth of GTL-16 Met-addicted cells
treated with increasing concentrations of MvDN30, DCD-1 or DCD-2 for 3 days. Graph represents percentage of average growth for each
treatment with respect to untreated cells. Samples are in quadruplicates, bars represent SEM. B. Anchorage-independent growth of HGF-
stimulated A549 cells treated with the different DN30-derived molecules (1.5 mM). Graph represents the percentage of the average colony growth
for each treatment with respect to HGF-treated cells. C. Anchorage-independent growth of GTL-16 cells treated with the indicated
concentrations of MvDN30, DCD-1 or DCD-2. Graph represents percentage of average colony growth for each treatment with respect to
untreated cells. *, Student’s t Test p< 0.05; **, Student’s t Test p< 0.01. Each point is the mean of at least triplicate values, bars: SEM. Data
reported in the figure are representative of at least three experiments done.
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cetuximab treatment by Met amplification (Bardelli et al.,
2013). First we analyzed the inhibitory properties in vitro,
on cells derived from this tumor expanded in mice. In this
setting DCD-1 inhibited cell growth by 30% and DCD-2 by
33% (Supplementary Figure 3). Then M162 tumor samples
were subcutaneously implanted in the right flank of immu-
nocompromised mice. Animals were randomized and
treated by intraperitoneal injection with DCD-1, DCD-2 or
vehicle. DCD-1 and DCD-2 delayed the appearance of
palpable tumors e including one mouse/group not devel-
oping tumor at all e and reduced tumor growth
(Figure 8A,B).4. Discussion
In recent years, targeted therapy became a major goal in can-
cer clinical management. The Met receptor e for its central
role in regulation of the invasive growth programe is included
in the panel of key oncogenes to be aimed (Smyth et al., 2014).
As a consequence, several drugs againstMet or HGF have been
developed and a number entered in clinical trials (Cui, 2014;
Parikh et al., 2014). Case reports of patients carrying Met-
amplified glioblastoma, gastric, esophageal or lung carci-
nomas showed a clear response to Met inhibitors (Catenacci
et al., 2011; Lennerz et al., 2011; Ou et al., 2011; Chi et al.,
2012). On the other hand, more than hundred ongoing Met-
targeted phase I/II/III trials are stuck on inconsistent results1
due to: (i) the use of wrong drugs, as in the case of molecules
not targeting Met (Michieli and Di Nicolantonio, 2013); (ii)
wrong patients, i.e. lack of selection in accrual, for inade-
quate/absent evaluation of the Met genetic status (Sheridan,
2014); (iii) wrong pharmacology, including unawareness of1 http://www.fda.gov/Drugs/InformationOnDrugs/Approved-
Drugs/default.htm.the ‘flare’ effect (Chaft et al., 2011). Given the fulfillment of
the last two points, novel Met inhibitors are still an unmet
medical need.
The antibody MvDN30, in principle, is a good candidate to
enter clinical trials. Its mechanism of action, wiping out Met
receptors from cell surface and releasing free Met extracel-
lular domains (acting as a ‘decoys’ with inhibitory properties),
proved to be effective against all forms of Met activation, both
ligand-dependent or -independent (Vigna and Comoglio,
2015). The limit of the molecule is the short half-life due to
the low molecular weight. To bypass this drawback, conven-
tional technologies based on conjugation with Poly Ethylene
Glycol (PEG) were exploited (Chapman, 2002). MvDN30 PEGyla-
tion not only reduced renal clearance but also increasedwater
solubility, protected from enzymatic degradation and limited
immunogenic and antigenic reactions (Vigna et al., 2015).
Nevertheless, the process requires cumbersome synthetic ef-
forts and it is associated with reduction of binding affinity.
Alternatively, the size of a protein drug may be increased by
molecular engineering. In this context, fusion proteins proved
to be effective, as in the case of albuferones, i.e. interferons
fused with human albumin, employed in the clinic for their
anti-viral activities (Chemmanur andWu, 2006). Human albu-
min has been also genetically fused to coagulation factors
(rVIIa-FP and rIX-FP) for the treatment of haemophilia pa-
tients (Metzner et al., 2013). A further example of a successful
fusion protein is ‘Etanercept’, a biologic modulator of inflam-
mation approved for the treatment of autoimmune diseases.
Thismolecule is generated by a soluble formof tumor necrosis
factor receptor linked to the Fc receptor for human IgG1
immunoglobulin (Scott, 2014). In our hands the attempt of
increasing the size of MvDN30 by an extra-tail of albumin
proved to be awkward (Vigna, unpublished results). As an
alternative, we modified the MvDN30 molecular weight by
duplication of the Fab constant domains. In a different context
(bispecific antibodies), fusion between variable regions has
been demonstrated to be functional (Wu et al., 2007).
Figure 6 e DCDs show improved pharmacokinetic profiles. A. Serum concentration kinetic of MvDN30, DCD-1 and DCD-2 after intraperitoneal
delivery in immunocompromised mice. B. Serum concentration kinetic of MvDN30, DCD-1, DCD-2 and chimeric DN30 mAb after intravenous
delivery in immunocompromised mice. Concentration values were determined by ELISA on mouse sera. Samples are in triplicates, bars represent
standard deviation. I.P.: intraperitoneal injection; I.V.: intravenous injection. Obtained pharmacokinetic parameters in the tables (lower panels A
and B). Cmax: maximal circulating concentration; t1/2 distr: distribution half-life; t1/2 elim: elimination half-life; tot AUC: total Area Under the
Curve; k elim: elimination constant.
M O L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 9 3 8e9 4 8 945MvDN30 derivatives with the predicted weight of 75 kDa were
generated. As expected, in solution these molecules sponta-
neously dimerize and oligomerize. In fact, the second con-
stant domain of both Fab chains gives rise to a second pair
of free cysteine residues, available for inter-molecule disulfide
bonds. From one side, themultimericmolecules have the high
molecular weight required for extending the half-life in theFigure 7 e DCDs inhibit Met-addicted tumor growth. Met-addicted GTL16
NOD/SCID mice. Animals were randomized and treated twice a week as f
mouse). A. IVIS Spectrum images of one representative mouse/group (upp
animal sacrifice (one/group, lower panel). B. Total bioluminescence derived
percentage of the average bioluminescent signal with respect to vehicle tre
reported in the figure are representative of two experiments done.circulation. From the other side, since the oligomers contain
more than one binding site, they potentially re-acquire
agonistic properties. However, careful analysis of Met phos-
phorylation and activation of down-stream pathways showed
that DCD-1 and DCD-2, while retaining a minimal residual
agonistic activity, were totally ineffective in activation of the
intracellular signaling and the ensuing invasive growthtumor cells expressing luciferase were intraperitoneally injected in
ollows: Vehicle, MvDN30, DCD-1 or DCD-2 (all molecules 8 nmol/
er panel) and of the tumor foci grown on the omentum collected after
from peritoneal tumor foci at the day of sacrifice. Graph represents the
ated group. Bars represent SEM; *, Student’s t Test p< 0.05. Data
Figure 8 e DCDs inhibit tumor implant and growth of a Met-amplified patient-derived colorectal carcinoma. Tumor specimens from the M162
‘xenopatient’, were subcutaneously implanted into the flank of NOD/SCID mice; animals were randomized into three groups and treated twice a
week as follows: Vehicle, DCD-1 or DCD-2 (both 7 nmol/mouse). A. Kinetic of tumor implant. Each symbol represents the percentage of tumor
negative animals at the indicated time point B. Kinetic of tumor growth. Each symbol represents the average tumor volume at the indicated time
point; bars: SEM. ***, two-way ANOVA p< 0.0001.
MO L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 9 3 8e9 4 8946biological response. It is thus concluded that multivalency of
the Dual Constant Domain Fabs does not mean ‘per se’ acqui-
sition of agonistic activity. This finding is in line with the
notion that the ability to stably dimerize receptors (including
Met) relies on the distance between the target molecules
engaged by the antibody (Cochran et al., 2001; Kai et al.,
2008). Moreover it is known that receptor dimerization e
although requirede is not necessarily sufficient for the activa-
tion of tyrosine kinase receptors (Schlessinger, 2014). A
behavior similar to the DCDs has in fact also been reported
for other inhibitory antibodies, e.g. matuzumab and cetuxi-
mab, inhibiting EGFR downstream signaling in the presence
of subliminal receptor phosphorylation (Yoshida et al., 2008).
We argue that, compared to a natural antibody, where the
hinge region confers a certain grade of flexibility (Roux et al.,
1997), DCD molecules are more rigid and therefore less prone
to the adaptation in the space required for induction of func-
tional dimerization.
Both DCDmolecules show improved pharmacokinetic pro-
file when compared to the parental MvDN30. The half life was
significantly extended after both intraperitoneal and intrave-
nous administration. After intraperitoneal administration
the DCDs maximal blood concentration was delayed but
reached higher levels than MvDN30. This reflects the time
lost in the transfer from the peritoneal cavity to the blood,
counterbalanced by the extra-time gained as a consequence
of reduced renal clearance. In absolute terms, this strategy in-
creases the half-life of MvDN30 in the range obtained by PEGy-
lation (Vigna et al., 2015). For the above considerations
regarding the synthetic efforts to generate PEG derivatives
and the reduction of their binding affinity, the described mo-
lecular engineering approach is preferable.
The improved pharmacokinetic profile of DCDs is followed
by enhanced potency in vivo, in pre-clinical settings of cancer
of two different tissues of origin: stomach and colon. Notably,
the ‘xenopatient’ model proved to be highly predictive of clin-
ical outcomes (Hidalgo et al., 2014).
All together these data suggest that the strategy of dupli-
cating the immunoglobulin constant domains by molecularengineering is potentially suitable to improve the therapeutic
effectiveness of other Fab fragments.Acknowledgments
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